Health
Clinical trial testing efficacy of antibody against SARS-CoV-2 begins – Medical Xpress
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
For the BLAZE-1 trial, UChicago is recruiting 22 participants to be treated with the LY-CoV555 antibody developed by Eli Lilly and Company in collaboration with AbCellera. The antibody was first identified by scientists at the National Institute of Allergy and Infectious Diseases and AbCe…
-
Business24 hours agoMacquarie names 3 small and mid-cap ASX REITs to buy this month
-
Noosa News24 hours agoCriminologists criticise Queensland premier’s definition of crime victim
-
General21 hours ago‘Worrying’: fresh NAPLAN results trend revealed
-
Business21 hours ago3 common investor biases to watch this earnings season